SCIENTIFIC PROGRAMME

DAY 1: Thursday, July 7, 2016

10.00 - 11.30

Round Table - ROOM 252 A
 

“Psoriasis by non-dermatologists: what you should know”

Chair: Luigi Naldi (Italy)

10:00 O001 - Psoriasis can kill, the visible murder - Carolina Cortéz Correa (Colombia)
10:15 O002 - The importance of screening for comorbidities - Gladys Leon Dorantes (Mexico)
10:30 O003 - Itch in psoriasis and its negative impact on patients' psyche - Wojciech Baran (Poland)
10:45 O004 - Screening campaigns in the general community - Minerva Gomez (Mexico)
11:00 O005 - Clinical manifestations and convential therapy for psoriasis - Emad Elgamal (Egypt)

         

Short Presentations Session - ROOM 252 B
 

“Late Breaking News"

Chairs: Luis Puig (Spain), Jo Lambert (Belgium)

10:00 P216 - CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts.
Ammar M.*, Jordan  C., Cao L., Lim E., souissi bouchlaka C., zaraa I., Anbunathan H., mokni M., doss N., Guttman-Yassky E., el gaaied  A., menter A., Bowcock A. (Tunis, Tunisia)
10:10 P217 - VEGF–A plays an essential role in itchy psoriasis by promoting epidermal hyperinnervation in imiquimod-induced psoriasiform model
Wong L.-S.*, Otsuka A., Kabashima K. (Kaohsiung, Taiwan, Province of China)
10:20 P218 - CF101 via A3AR Activation inhibits IL-17 and IL-23 in Human Keratinocytes
Cohen S.*, Barer F., Fishman P. (Petach Tikva, Israel)
10:30 P219 - Comparable Efficacy but longer Drug Survival of Biologics vs conventional systemic Therapy – an Analysis of the Swiss Registry for Psoriasis
Maul J.-T.*, Kolios A., Djamei V., Meier B., Czernielweski J., Yawalkar N., Laffitte E., Spehr C., Anliker M., Streit M., Augustin M., Rustenbach S., Conrad C., Hafner J., Boehncke W.-H., Borradori L., Gilliet M., Itin P., French L., Haeusermann P., Navarini A. (Zürich, Switzerland)
10:40 P220 - Does tumour necrosis factor inhibitor therapy affect the incidence of myocardial infarction in patients with psoriasis?
Shaaban D., Al-Mutairi N.* (Kuwaitf city, Kuwait)
10:50 P221 - Reduced Incidence of Dementia in Patients with Psoriasis: A National Population-Based Matched-Cohort Study
Chiu H.-Y.*, Chang W.-L., Huang W.-F., Tsai Y.-W., Lin S.-J., Tsai T.-F. (Hsinchu, Taiwan, Province of China)
11:00 P222 - GP2015, a proposed etanercept biosimilar, has equivalent efficacy, safety and immunogenicity to etanercept originator product in patients with chronic plaque-type
Griffiths C. E., Thaci D.*, Gerdes S., Pulka G., Kingo K., Weglowska J., Reich K., Afonso M. (Lubeck, Germany)
11:10 P223 - TIME COURSE OF IXEKIZUMAB DRUG LEVELS AND THE RELATIONSHIP AT WEEK 60 TO EFFICACY IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Reich K.*, Choi S. L., Jackson K., Mallbris L., Blauvelt A. (Hamburg, Germany)
11:20 P224 - Secukinumab Exhibits Low Immunogenicity During 3 Years of Treatment in Subjects with Moderate to Severe Plaque Psoriasis
Reich K.*, Blauvelt A., Armstrong A. W., Warren R. B., Messina I., Ren M., Liang E., Spindeldreher S., Fox T., Papavassilis C., Bruin G. (Hamburg, Germany) 


__________________________________________________

13.00 - 14.00:            ICE-BREAKER IN THE EXHIBITION AREA

___________________________________________________

 

14.00 - 16.00

PLENARY SESSION 1 - AMPHITHEATRE BLEU
 

“Psoriasis as a Systemic Inflammatory disease: Genetic and immunologic background”

Chairs: Lone Skov (Denmark), Maria Lorna Frez (Philippines), Peter van de Kerkhov (Netherlands)

14:00 O006 - Microbiome and Psoriasis: up to date. - Thomas Luger (Germany)
14:20 O007 - The relationship between Psoriasis and the autoinflammatory diseases - HJ Song (Korea)
14:40 O008 - New insights in Psoriasis genetics and epigenetics - Mario Bittar (Argentina)
15:00 O009 - Cytokine networks in Psoriasis and its comorbidities - Stefan Beissert (Germany)
15:20 O010 - Psoriasis and cardiovascular disease: do they share the same inflammatory pathways? - Nehal Mehta (USA)

___________________________________________________

16.00 - 16.30:            BREAK AND POSTER VIEWING

___________________________________________________

16.30 - 18.00

WORKSHOPS

W 1 - Internal Medicine and Psoriasis - ROOM 252 AB
 

Chairs: Carolina Velasquez (Colombia), Mehmet Ali Gürer (Turkey), Nikolai Tsankov (Bulgaria)

16:30 O011 - Psoriasis and Cancer: is everything related to therapies? - Peter van de Kerkhof (Netherlands)
16:45 O012 - Ulcerative colitis, Crohn and Psoriasis: common physiopathological pathways? – Nancy Podoswa (Mexico)
17:00 O013 - Metabolic syndrome and psoriasis. - Akihiko Asahina (Japan)
17:15 O014 - Psychological comorbidities. - Paolo Gisondi (Italy)
17:30 P001 - RISK OF SELF-HARM AND NON-FATAL SUICIDE ATTEMPTS, AND COMPLETED SUICIDE IN PATIENTS WITH PSORIASIS – A POPULATION-BASED COHORT STUDY
Egeberg A.*, Hansen P., Gislason G., Skov L., Mallbris L. (Copenhagen, Denmark)
17:35 P002 - PSORIATIC ARTHRITIS AND PRIMARY SCLEROSING CHOLANGITIS: ROLE OF METHOTREXATE?
Sahel H.*, Khettaoui S., Belazouz A., Benmohand C., Otsmane F., Bouadjar B. (Alger, Algeria)

 

W 2 - Psoriasis Controversy I: Biosimilars - AMPHITHEATRE BLEU
 

Moderators: Diamant Thaçi (Germany), Claudia de la Cruz (Chile)

16:30 O015 - It’s the economy, stupid.  Maintaining access to therapy. - Kim Papp (Canada) 
17:15 O016 - Innovate or die, stupid.  Providing better therapies. - Alan Menter (USA)

 

W 3 - Treatments in Psoriatic Arthritis in adults and children - ROOM 251
 

Chairs: Irene Araya (Chile), Ignacio Dei Cas (Argentina)

16:30 O017 - Influence of cutaneous involvement in deciding how to treat psoriatic arthritis. - Axel Villani (France)
16:45 O019 - Biologics in the treatment of psoriatic arthritis in children. Present and future. - Frank Behrens (Switzerland)
17:00 O020 - Treatment of psoriatic arthritis: traditional DMARDs and new therapies, approaches and recommendations? - Kurt de Vlam (Belgium)
17:15 P003 - IXEKIZUMAB PROVIDES IMPROVEMENTS THROUGH 52 WEEKS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (BDMARD) NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
Gottlieb A. B.*, Husni M. E., Shuler C. L., Burge R., Lin C.-Y., Lee C. H., Gladman D. D. (Boston, United States)
17:20 P004 THE ACCURACY OF EARP (EARLY ARTHRITIS FOR PSORIATIC PATIENTS) IN SCREENING FOR PSORIATIC ARTHRITIS AMONG ADULT FILIPINO PATIENTS
Llana M. V. L.*, Aquino-Villamin M., Sevilleja J. E., Carpio B., Regalado-Morales E., Lapitan-Torres A. A. (Manila, Philippines)
17:25 P005 MICRORNA BIOMARKERS FOR PSORIASIS ARTHRITIS – EARLY RESULTS
Paulsen I. W.*, Munk H., Grum-Schwensen B., Jemec G. B. E., Svendsen A. J., Troelsen J., Junker P., Pedersen O. B. (Næstved, Denmark)


18.00 - 19.30 
 

PATIENT ASSOCIATIONS MEETING - ROOM 251
 

18:00 - Welcome Address
Silvia Fernández Barrio – President of LATINAPSO
18:10 - Uncover needs and medical patient relationship
Dr. Carla Castro – Dr. Gabriel Magariños
18:50 - WHO Resolution: Impetus for Change
Sophie Andersson – Head Operations of IFPA & Lars Ettarp – President of IFPA

 

DAY 2: Friday, July 8, 2016

 

8.30 - 10.00  

WORKSHOPS

W 4 - Therapeutic targets in psoriasis - ROOM 251
 

Chairs: Graciela Pellerano (Argentina), Thomas Luger (Germany)

8:30 O021 - New topical targets. - Matias Maskin (Argentina)
8:45 O022 - The role of genetics in treatment stratification. - Antonio Costanzo (Italy)
9:00 O023 - Are PPARs a promising target to treat psoriasis? - Ricardo Romiti (Brazil)
9:15 O024 - Small molecules: JAK inhibitors, Phosphodiesterase inhibitors and A3 adenosine receptor agonists. - Ulrich Mrowietz (Germany)
9:30 O025 - Anti-IL 17 and Anti- IL 23: where are we and where do we go? - Kenneth Gordon (USA)
09:45 P006 - ACUTE SERUM AMYLOID A IS PRODUCED BY KERATINOCYTES MAINLY BY IL-17A ACTIVATION AND ITS EXPRESSION COULD CONTRIBUTE TO THE VICIOUS CIRCLE OF PSORIASIS PATHOGENESIS
Elodie C.*, Franck M., François-Xavier B., Amandine B.-M., Camille P., Pierre L., Gerard G., Jean-Claude L. (Poitiers, France)
09:50 P007 - THE PSORIASIS–ASSOCIATED IL-17A DISTURBS SKIN BARRIER FORMATION IN 3D ORGANOTYPIC SKIN MODELS
Pfaff C.*, Marquardt Y., Czaja K., Lüscher B., Baron J. (Aachen, Germany)
09:55 P008 - NOVEL TH17-CELL CYTOKINE MEDIATES THE HIGH ANTI-VIRAL COMPETENCE OF PSORIATIC SKIN
Wolk K.*, Witte K., Witte E., Raftery M., Kokolakis G., Philipp S., Schönrich G., Prösch S., Volk H.-D., Sterry W., Sabat R. (Berlin, Germany) 

 

W 5 - Psoriasis Controversy II: Related comorbidities - Is there now enough evidence that controlling psoriasis really decreases cardiovascular risk? - ROOM 252 AB
 

Chairs: Fernando Stengel (Argentina), Marc Bourcier (Canada)

8:30 O026 - Yes - Jashin Wu (USA)
9:15 O027 - No - Tamar Nijsten (Netherlands)
 

W 6 - Non-biological systemic treatments today: need for repositioning? - AMPHITHEATRE BLEU
 

Chairs: Skaidra Valiukeviciene (Lithuania), Tatiana Riveros (Chile), Nora Kogan (Argentina)

8:30 O028 - Fumarates PML – how to monitor and can it still be considered as safe as before? - Sandra Philipp (Germany)
8:45 O029 - Methotrexate - s.c. versus oral, monitoring of the liver toxicity. - Rolland Gyulai (Hungary)
9:00 O030 - Cyclosporine - use it in case of preexising arterial hypertension?
Relevant changes in kidney function, what is normal, when to stop? - Fernando Valenzuela (Chile)
9:15 O031 - New and upcoming small molecules. - Richard Langley (Canada)
09:30 P009 - METHOTREXATE IN THE TREATMENT OF SEVERE PSORIASIS (PSORIATIC ARTHRITIS, ERYTHRODERMIC PSORIASIS, PUSTULAR PSORIASIS)
Omar B. S.* (Tlemcen, Algeria)
09:35 P010 - RIFAMPICIN – MORE THAN 20-YEAR EXPERIENCE OF ITS USE IN PSORIASIS
Grozdev I.*, Tsankov N. (Brussels, Belgium)
09:40 P011 - ENHANCED LIVER FIBROSIS TEST (ELF) IN PSORIASIS, PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS PATIENTS: A DAILY PRACTICE COMPARISON WITH PROCOLLAGEN-3 N-TERMINAL PEPTIDE (P3NP).
Van Der Voort E.*, wakkee M., Nijsten T. (Rotterdam, Netherlands)

___________________________________________________

10.00 - 10.30:            BREAK AND POSTER VIEWING

___________________________________________________


10.30 - 12.30

PLENARY SESSION 2 - AMPHITHEATRE BLEU
 

“Psoriasis beyond T cells. Searching for other actors (Keratinocytes, mast cells, etc)”

Chairs: Min Zheng (China), Georg Stingl (Austria), Peter van de Kerkhof (Netherlands)

10:30 O032 - Keratinocytes and antimicrobial peptides in psoriasis. - Antonio Constanzo (Italy)
10:50 O033 - Mast cells and neutrophils in psoriasis. - Kristian Reich (Germany)
11:10 O034 - Dermal and epidermal microenvironment in psoriasis plaque - Jörg Christoph Prinz (Germany)
11:30 O035 - Plasmacytoid dentritic cells and IFN-alpha production, their role in psoriasis variants, and their potential in psoriasis treatment - Curdin Conrad (Switzerland)

___________________________________________________

12.00 - 14.30:            BREAK AND POSTER VIEWING

___________________________________________________

 
14.30 - 16.00

WORKSHOPS

W7 - Psoriasis: management in different moments (children, seniors, pregnancy, breast feeding) - ROOM 252 AB
 

Chairs: Fatimata Ly (Senegal), Hidemi Nakagawa (Japan)

14:30 O036 - My patient is on systemic treatment and is pregnant! What do I have to do? - Luna Azulay (Brazil)
14:45 O037 - Psoriasis treatment in the elderly: what about frailty and multimorbidity? - Yoshinori Umezawa (Japan)
15:00 O038 - Children systemic therapies today: from the evidence to the clinical practice. - Marieke Seyger (Netherlands)
15:15 O039 - Recommendations for patients under systemic treatment in case of traveling and surgery. - Alex Abarca Duran (Costa Rica)
15:30 P012 - SCALP PSORIASIS AND BIOLOGIC AGENTS: A COMPARATIVE STUDY FROM A TERTIARY PSORIASIS REFERRAL CENTRE
Fotiadou C.*, Lazaridou E., Sotiriou E., Apalla Z., Ioannides D. (Thessaloniki, Greece)
15:35 P013 - PRELIMINARY RESULTS OF A MULTICENTER RETROSPECTIVE STUDY ON THE USE OF BIOLOGICS IN PSORIASIS IN ELDERLY PATIENTS IN FRANCE.
Beneton N.*, Mahé E., Bauchet A., Chaby G., Quiles N., Pallure V., Khemis A., Maccari F., Begon E., Boyé T. et Resopso (Le Mans, France)
15:40 P014 - TREATMENT OF GENERALIZED PUSTULAR PSORIASIS DURING PREGNANCY: A REAL CHALLENGE
Zaouak A., Sassi W., Hammami H., Fenniche S.* (Tunis, Tunisia)

 

W8 - Topical treatments today - ROOM 251
 

Chairs: Leana Quintanilla (El Savador), Riad Mashal (Palestine), Asja Prohic (Bosnia Herzegovina)

14:30 O040 - Adherence: the first goal in topical treatments. - Norito Katoh (Japan)
14:45 O041 - Which is the role of topical therapy in nail psoriasis? - Myrto-Georgia Trakatelli (Belgium)
15:00 O042 - Corticosteroids with and without vitamin D. Still the first choice? - Lars Iversen (Denmark)
15:15 O043 - Emerging topical drugs. - Luis Mazzuoccolo (Argentina)
15:30 P015 - HYDROGEL FORMULATION OF POLY(LACTIC ACID) (PLA) NANOPARTICLES CONTAINING JAK/STAT INHIBITORS FOR TOPICAL TREATMENT OF PSORIASIS
Boisgard A.-S.*, Lamrayah M., Kirilov P., Verrier B. (Lyon, France)
15:35 P016 - TURMERIC AS A NEW TOPICAL TREATMENT FOR MILD TO MODERATE PLAQUE PSORIASIS: A PROSPECTIVE, RANDOMIZED HALF-BODY COMPARATIVE STUDY
Mansouri P.*, Rajabi M., Sarafian G., Chalangari R., Martits-Chalangari K. (Tehran, Iran, Islamic Republic Of)
15:40 P017 - LIPOSPHERE MEDIATED CODELIVERY OF TACROLIMUS AND CURCUMIN FOR TREATMENT OF PSORIASIS
Jain A.*, Doppalapudi S., Khan W. (HYDERABAD, India)

W9 - Patients follow up with biologics and other treatments (How often? What to do?) - AMPHITHEATRE BLEU
 

Chairs: Tomaz Lunder (Slovenia), Manuel Franco (Colombia), Fernando Stengel (Argentina)

14:30 O045 - Classical: a. Methotrexate, b. Cyclosporine, c. Acitretin - Cesar Gonzalez (Colombia)
14:45 O046 - Biologicals inhibiting TNF, IL 12/23 and IL 17: What to use? How to choose? - Hervé Bachelez (France)
15:00 O047 - Small molecules: a.Apremilast, b.Tofacitinib - Craig Leonardi (USA)
15:15 O048 - Combination therapies - Céline Busard (Netherlands)
15:30 P018 - LOW DOSE CYCLOSPORINE HAS AN EFFECT OF IMMUNOMODULATION, NOT IMMUNOSUPPRESSION, IN KOREAN PATIENTS WITH PSORIASIS
Choi J. H., Shin E.-J., Shin M. K., Kim N.-I.* (Seoul, Korea, Republic Of)
15:35 P019 - HEPATOTOXICITY WITH METHOTREXATE THROUGH 25 YEARS PHARMACOVIGILANCE SURVEY
Alkathiri M.*, youssef S., karray M., alaoui F., abdelhedi N., jaber K., dhaoui R., doss N. (tunis, Tunisia)
15:40 P020 - CURRENT STATUS OF OBSERVATIONS OF MALIGNANCIES IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY (PSOLAR) STUDY
Fiorentino D.*, Lebwohl M., Ho V., Langley R., Goyal K., Fakharzadeh S., Calabro S., Langholff W. (Redwood City, United States)

Workshop kindly sponsored by Pfizer.
 

___________________________________________________

16.00 - 16.30:            BREAK AND POSTER VIEWING

___________________________________________________


18.00 - 19.30

PIN NATIONAL REPRESENTATIVES MEETING - ROOM 251

 

DAY 3: Saturday, July 9, 2016

 

8.30 - 10.00  

WORKSHOPS

W10 - Therapeutic optimization in psoriasis - AMPHITHEATRE BLEU
 

Chairs: Guadalupe Villanueva (Mexico), Juan Raul Castro Ayarza (Colombia), Wolf-Henning Boehncke (Switzerland)

8:30 O049 - Treatment goals and transition therapies: from guidelines to the real world. - Cristina Echeverria (Argentina)
8:45 O050 - Treat to target in psoriasis and psoriatic arthritis. - Alexa Kimball (USA)
9:00 O051 - Immunogenicity impact in treatment choice and transition therapies. - Karien Bloem (Netherlands)
9:15 O052 - Optimization-Combination treatment. - Phyllis Spuls (Netherlands)
09:30 P021 - BIOLOGIC THERAPY AND INTRODUCTION OF BIOSIMILARS FOR SEVERE PSORIASIS IN KAUNAS, LITHUANIA
Sakalauskiene I.*, Petraityte I., Valiukeviciene S. (Kaunas, Lithuania)
09:35 P022 - PSORIATIC NAILS: A PROSPECTIVE CLINICAL STUDY
Jendoubi F.*, Jaber K., Rabhi F., Youssef S., Dhaoui M. R., Gargouri S., Doss N. (Tunis, Tunisia)
09:40 P023 - FACTORS ASSOCIATED WITH SUCCESSFUL SWITCHING BETWEEN BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS IN DAILY DERMATOLOGICAL REAL-LIFE PRACTICE: THE RESOSWITCH STUDY
Dabouz F., Khemis A., Lahfa M., Maccari F., Chaby G., Beneton N., Boye T., Esteve E., Mahé E., Begon E., Pauwels C., Bernard P., Reguiai Z.* et RESOPSO (Reims, France)


W
11 -  Biologics today and in the future - ROOM 252 AB
 

Chairs: Angela Londono (Colombia), Hugo Schönenberger de Oliveira (Portugal), Esteban Dauden (Spain)

8:30 O053 - The impact of biologics in psoriasis comorbidities. - Yves Poulin (Canada)
8:45 O054 - New molecules in the pipeline. - Kim Papp (Canada)
9:00 O055 - Health economics and biologics prescription: worldwide differences. - Matthias Augustin (Germany)
09:15 P024 - CHARACTERIZATION OF THE SKIN TH17 TRANSCRIPTIONAL PROFILES IN PSORIATIC PATIENTS UNDER ADALIMUMAB BIOTHERAPY
Morel F.*, Couderc E., Buffière-Morgado  A., Delwail A., Favot L., Jégou J.-F., Guillet G., Lecron J.-C. (Poitiers, France)
09:20 P025 - EFFICACY AND SAFETY OF IXEKIZUMAB OVER FOUR YEARS OF OPEN-LABEL TREATMENT IN A PHASE 2 STUDY IN CHRONIC PLAQUE PSORIASIS
Gordon K.*,  Leonardi C., Blauvelt A., Zachariae C., Cameron G., McKean-Matthews M.,  Ridenour T., Lebwohl M. (Chicago, United States)
09:25 P026 - EFFICACY AND SAFETY OF IXEKIZUMAB IN PSORIASIS PATIENTS WHO FAILED TO REACH PASI 75 ON ETANERCEPT: SUBANALYSIS OF UNCOVER-3
Blauvelt A., Papp K.*, Puig L., Dutronc Y., Kerr L., Mallbris L., Ilo D., Weisman J., Augustin M. (Waterloo, Canada)

 

W12 - Phototherapy - ROOM 251
 

Chairs: Lajos Kemeny (Hungary), Débora Kaplan (Argentina), George-Sorin Tiplica (Romania)

8:30 O056 - The relation between phototherapy and skin cancer: how can we minimize the risks? - Hernan Correa (Chile)
8:45 O057 - Targeted UVB phototherapy: indications and limitations. -  Speaker to be confirmed
9:00 O058 - Home phototherapy: when and how? Is it safe? - Vigfus Sigurdsson (Netherlands)
9:15 O059 - Phototherapy in pediatric patients. - Joanna Narbutt (Poland)
09:30 P027 - CODED UNANI FORMULATIONS (UNIM 401 SYSTEMICALLY AND UNIM 403 TOPICALLY) AND PUVASOL IN CHRONIC PLAQUE PSORIASIS: NON-INFERIORITY RANDOMIZED CONTROLLED CLINICAL TRIAL
KHANNA N.*, NAZLI T., SIDDIQUI K. M., KALAIVANI M., RAHMAN R. U. (NEW DELHI, India)
09:35 P028 - POSITIVELY AND NEGATIVELY CHARGED LIPOSOMES AS CARRIERS FOR TRANSDERMAL DELIVERY OF PSORALEN: IN VITRO AND IN VIVO EVALUATION
Doppalapudi S.*, Jain A., Khan W. (Hyderabad, India) 

________________________________________________

10.00 - 10.30:            BREAK AND POSTER VIEWING

___________________________________________________

 
10.30 - 12.30

PLENARY SESSION 3 - AMPHITHEATRE BLEU   
               

“Patient-oriented therapies” (personalized / custom-made)

Chairs: Edgardo Chouela (Argentina), AJ Kanwar (India), Lluis Puig (Spain)

10:30 O060 - Genetic background and treatment response: personalized therapies? - Georg Stingl (Austria)
10:50 O061 - Phenotyping in psoriasis: a major clinical research project for PIN - Louis Dubertret (France)
11:10 O062 - Pharmacogenetics and pharmacogenomics in psoriasis: today and in the future. - Warren Richard (UK)
11:30 O063 - The influence of health resources in the access to drugs: differences around the world. - José Manuel Carrascosa (Spain)
11:50 O064 - Therapeutic patient education: added value in psoriasis? - Jo Lambert (Belgium) 

 

14.00 - 15.30

WORKSHOPS

W13 - Psoriasis in children - ROOM 251
 

Chairs: Carla Castro (Argentina), Laura Alvarez Morales (Costa Rica), Paula Luna (Argentina)

14:00 O065 - Epidemiology, diagnosis and prognosis. Emmanuel Mahé (France)
14:15 O066 - Topical and systemic therapies for children today. - Emmanuel Mahé (France)
14:30 O067 - How to balance long-term efficiency and safety? - Anna Belloni (Italy)
14:45 O068 - Comorbidities and beyond. - Vicenç Torrente-Segarra (Spain)
15:00 P029 - « THÉO ET LES PSORIANAUTES » (THÉO AND THE PSORIANAUTES) A SERIOUS GAME DEVELOPED FOR CHILDREN WITH PSORIASIS
Aubin M., Piérard N., Mahé E.* (Argenteuil, France)
15:05 P030 - MANAGEMENT OF CHILDHOOD PSORIASIS IN FRANCE. A NATIONAL SURVEY AMONG GENERAL PRACTITIONERS, PEDIATRICIANS, AND DERMATOLOGISTS
Mahé E.*, Bursztejn A.-C., Phan A., Corgibet F., Beauchet A., Sigal M.-L. (Argenteuil, France)
15:10 P031 - PRE- AND NEONATAL RISK FACTORS FOR DEVELOPMENT OF PSORIASIS
Egeberg A.*, Mallbris L., Gislason G., Skov L. (Copenhagen, Denmark) 

 

W14 - Registries (regional differences, uncovered needs, communication networks, access to patients data) - ROOM 252 AB  
 

Chairs: Luigi Naldi (Italy), Rolland Gyulai (Hungary), Nejib Doss (Tunisia)

14:00 O069 - Goals and limitations in psoriasis registries, regional differences and regulatory issues. - Edgardo Chouela (Argentina)
14:15 O070 - The Biobadaderm registry experience: Spain leading the way. - Ignacio Garcia Doval (Spain)
14:30 O071 - PSOLAR:  a registry in maturity - Alexa Kimball (USA)
14:45 O072 - How to interpret registry data? How does registry data match with RCT data and results from meta-analysis? -Alexander Nast (Germany)
15:00 P032 - PSYCHOMETRIC EVALUATION OF THE SELF-ASSESSMENT OF PSORIASIS SYMPTOMS (SAPS)-CLINICAL TRIAL AND THE SAPS-REAL WORLD PATIENT REPORTED OUTCOMES
Armstrong A.*, Banderas B., Sundaram M., Foley C., Ojo F., Shields A. L. (Los Angeles, CA, United States)
15:05 P033 - EPIDEMIOLOGICAL DATA IN CHILDHOOD PSORIASIS
Dencheva I., Botev I.*, Miteva L. (Sofia, Bulgaria) 

 

W15 - Life quality, adherence and access to treatment - AMPHITHEATRE BLEU
  

Chairs: Martine Bagot (France), Lars Ettarp (Sweden), Simon Gusis (Argentina)

14:00 O073 - Access to medications in developing countries: itolizumab, biosimilars and copies - Alur s. Kumar (India)
14:15 O074 - Coping strategies and the role of patient social network: tools to decrease life quality impact? - Francesca Sampogna (Italy)
14:30 O075 - Could early high effective therapies decrease the burden of the psoriatic disease? - Jean-François Nicolas (France)
14:45 O076 - Whole person care, quality of life and health care systems - Matthias Augustin (Germany)
15:00 O077 - The role of physicians, family and social environment to increase adherence: creating new strategies - Christine Bundy (UK)
15:15 P034 - THE ROLE OF CLINICIANS, PATIENTS AND SOCIAL FACTORS IN POOR ADHERENCE: CREATING NEW UNDERSTANDING AND CONSULTATION SKILLS TO INCREASE ADHERENCE AND SELF-MANAGEMENT PSORIASIS PATIENTS
Bundy C.* (Manchester, United Kingdom)
15:20 P035 - THE NAIL PSORIASIS SEVERITY INDEX (NAPSI) 13 YEARS LATER:  VALIDATION OF AN INSTRUMENT TO ASSESS PSORIATIC NAIL INVOLVEMENT
Jefferson J., Manhart R., Moore J., Scher R., Rich P.* (Portland, United States)
15:25 P036 - QUALITY OF LIFE AND COMORBIDITIES IN PALMOPLANTAR PUSTULOSIS – A CROSS SECTIONAL STUDY ON 102 PATIENTS
Trattner H.*, Steiner I., Tanew A. (Wien, Austria)  

 

 _____________________________________________

15.30 - 16.00:            BREAK AND POSTER VIEWING

______________________________________________

 

16.00 - 18.00

CLOSING PLENARY SESSION - AMPHITHEATRE BLEU 
 

“Looking into the future” 

Chairs: Nélida Raimondo (Argentina), Frank Behrens (Switzerland)

16:00 O078 - Research: Frank Nestlé (UK)
16:30 O079 - Research: James Krueger (USA)
17:00 O080 - Therapeutics: Lluis Puig (Spain),
17:30 O081 - Therapeutics: Carle Paul (France)

 

 

 

14:30 O045 Classical: a. Methotrexate, b. Cyclosporine, c. Acitretin - Cesar Gonzalez (Colombia)

14:45 O046 Biologicals inhibiting TNF, IL 12/23 and IL 17: What to use? How to choose? - Hervé Bachelez (France)

15:00 O047 Small molecules: a.Apremilast, b.Tofacitinib - Craig Leonardi (USA)

15:15 O048 Combination therapies - Céline Busard (Netherlands)

15:30 P018 LOW DOSE CYCLOSPORINE HAS AN EFFECT OF IMMUNOMODULATION, NOT IMMUNOSUPPRESSION, IN KOREAN PATIENTS WITH PSORIASIS

Choi J. H., Shin E.-J., Shin M. K., Kim N.-I.* (Seoul, Korea, Republic Of)

15:35 P019 HEPATOTOXICITY WITH METHOTREXATE THROUGH 25 YEARS PHARMACOVIGILANCE SURVEY

alkathiri M.*, youssef S., karray M., alaoui F., abdelhedi N., jaber K., dhaoui R., doss N. (tunis, Tunisia)

15:40 P020 CURRENT STATUS OF OBSERVATIONS OF MALIGNANCIES IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY (PSOLAR) STUDY

Fiorentino D.*, Lebwohl M., Ho V., Langley R., Goyal K., Fakharzadeh S., Calabro S., Langholff W. (Redwood City, United States)